The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Do Impotent Men With Diabetes Have More Severe Erectile Dysfunction and Worse Quality of Life Than the General Population of Impotent Patients?
Abstract
OBJECTIVE—Little is known regarding how diabetic men with erectile dysfunction (ED) differ from the general population of impotent men. The primary objective of this study was to compare disease-specific health-related quality of life (HRQOL) and severity of ED in impotent men with and without diabetes. RESEARCH DESIGN AND METHODS—Validated functional and HRQOL questionnaires (including the International Index of Erectile Function, the Sexual Self-Efficacy Scale, and the Psychological Impact of Erectile Dysfunction scales) were administered to patients in an ED disease registry. Men with ED and a history of diabetes (n = 20) were compared with men with ED and no history of diabetes (n = 90) at baseline and at the 12-month follow-up. RESULTS—Diabetic impotent men reported worse erectile function and intercourse satisfaction at baseline, and ED had a greater impact on their emotional life. Diabetic men with ED had significantly different trends over time in the Erectile Function (P < 0.001), Intercourse Satisfaction (P < 0.013), Sexual Desire (P < 0.016), Overall Satisfaction (P < 0.023), and the Sexual Experience-Psychological Impact domains (P < 0.002). In addition, there was a trend toward a difference over time in the Emotional Life-Psychological Impact domain (P < 0.067). CONCLUSIONS—Impotent men with diabetes present with worse ED than nondiabetic men with ED, resulting in worse disease-specific HRQOL in the diabetic men. Although diabetic patients initially respond well to ED treatment, responses do not appear to be durable over time. Therefore, clinicians must provide longer-term follow-up when treating ED in diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Diabetic men with ED also have significantly worse disease-specific health-related quality of life (Penson et al 2003).”
From Tadalafil in the treatment of erectile dysfunction (2008) · cites this paper as Penson et al 2003
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oral Sildenafil in the Treatment of Erectile Dysfunction
Goldstein, I., Lue, T. F., Padma-Nathan, H., Rosen, R. C., Steers, W. D., & Wicker, P. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382001 · Cited by 2,120
Self-citationThe Concepts of Power Analysis
Cohen, J. (1977) · Statistical Power Analysis for the Behavioral Sciences · doi:10.1016/b978-0-12-179060-8.50006-2 · Cited by 299
Research works printed but not linked: 13
- Siu SC, Lo SK, Wong KW, Ip KM, Wong YS: Prevalence of and risk factors for erectile dysfunction in Hong Kong diabetic patients. Diabet Med 18:732–738, 2001 · DOI
- Fedele D, Bortolotti A, Coscelli C, Santeusanio F, Chatenoud L, Colli E, Lavezzari M, Landoni M, Parazzini F, on behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici: Erectile dysfunction in type 1 and type 2 diabetics in Italy. Int J Epidemiol 29:524–531, 2000 · DOI
- Bacon CG, Hu FB, Giovannucci E, Glasser DB, Mittleman MA, Rimm EB: Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 25:1458–1463, 2002 · DOI
- Rendell MS, Rajfer J, Wicker PA, Smith MD: Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial: Sildenafil Diabetes Study Group. JAMA 281:421–426, 1999 · DOI
- De Berardis G, Franciosi M, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Pellegrini F, Sacco M, Tognoni G, Valentini M, Nicolucci A: Erectile dysfunction and quality of life in type 2 diabetic patients: a serious problem too often overlooked. Diabetes Care 25:284–291, 2002 · DOI · Paper page
- Latini DM, Penson DF, Colwell HH, Lubeck DP, Mehta SS, Henning JM, Lue TF: Psychological impact of erectile dysfunction: validation of a new health related quality of life measure for patients with erectile dysfunction. J Urol 168:2086–2091, 2002 · DOI
- OLeary MP, Fowler FJ, Lenderking WR, Barber B, Sagnier PP, Guess HA, Barry MJ: A brief male sexual function inventory for urology. Urology 46:697–706, 1995 · DOI
- Libman E, Rothenberg I, Fichten CS, Amsel R: The SSES-E: a measure of sexual self-efficacy in erectile functioning. J Sex Marital Ther 11:233–247, 1985 · DOI
- Rosen R, Riley A, Wagner G, Osterloh I, Kirkpatrick J, Mishra A: The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49:822–830, 1997 · DOI · Paper page
- Dey J, Shepherd MD: Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 77:276–282, 2002 · DOI
- Melman A, Gingell JC: The epidemiology and pathophysiology of erectile dysfunction. J Urol 161:5–11, 1999 · DOI · Paper page
- Heaton JP, Lording D, Liu SN, Litonjua AD, Guangwei L, Kim SC, Kim JJ, Zhi-Zhou S, Israr D, Niazi D, Rajatanavin R, Suyono S, Benard F, Casey R, Brock G, Belanger A: Intracavernosal alprostadil is effective for the treatment of erectile dysfunction in diabetic men. Int J Impot Res 13:317–321, 2001 · DOI
- Litwin MS, Nied RJ, Dhanani N: Health-related quality of life in men with erectile dysfunction. J Gen Intern Med 13:159–166, 1998 · DOI · Paper page
Cited by
Tadalafil in the treatment of erectile dysfunction
Coward, R., & Carson, C. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3336 · Cited by 138
Metadata
- Authors
- Penson, D. F., Latini, D. M., Lubeck, D. P., Wallace, K. L., Henning, J. M., & Lue, T. F.
- Affiliations
- Section of Urology, VA Puget Sound Health Care System, and the Department of Urology, University of Washington, Seattle, Washington
- Department of Urology, University of California—San Francisco, San Francisco, California
- TAP Pharmaceutical Products, Inc., Lake Forest, Illinois
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-04-01
- Volume
- 26
- Issue
- 4
- Pages
- 1093-1099
- ISSN
- 0149-5992
- 1935-5548
- Cited by
- 175
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
